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Case Report
Sodium glucose co-transporter 2 inhibitors in patients
with resistant hypertension: a case study
Amira Obeid, Mark Pucci, Una Martin and Wasim Hanif
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Lesson
Sodium glucose co-transporter 2 inhibitors lower blood
pressure by osmotic diuresis and can be considered in dia-
betic patients with resistant hypertension.
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Case presentation
A 68-year-old male patient with a medical history of
long-standing hypertension, ischaemic heart disease,
obesity, type 2 diabetes mellitus and rheumatoid arth-
ritis was referred by his general practitioner to the
hypertension clinic in May 2007, due to uncontrolled
hypertension despite three antihypertensive agents at
maximum tolerated doses (ramipril, felodipine and
atenolol). His mean daytime blood pressure at the
time of referral was 168/99mmHg. He was thoroughly
investigated for secondary causes of hypertension, but
none were found. His antihypertensive medication
regimen was progressively optimised over many
years, taking into account intolerances, adverse eﬀects
and co-morbidities. His medications at the time of the
addition of canagliﬂozin can be seen in Table 1.
In view of apparent resistance to treatment, the
patient was admitted to hospital for directly observed
therapy in June 2013 to exclude non-adherence.
His adherence was also conﬁrmed on two separate
occasions in 2014 when urinary drug screening
became routinely available. Renal denervation
(radio-frequency ablation of the renal sympathetic
nerves surrounding the renal arteries) was conducted
in October 2013. This had no eﬀect, and in fact his
blood pressure in June 2014 was higher with a mean
daytime blood pressure of 181/105mmHg.
The patient was started on the sodium glucose co-
transporter 2 inhibitor canagliﬂozin 100mg in May
2015 in view of a high body mass index of 38 and
suboptimal diabetes control (HbA1c of 103mmol/
mol). This was uptitrated to 300mg daily. A signiﬁcant
reduction in the patient’s blood pressure occurred with
the best clinic reading being 137/80mmHg. The HbA1c
also reduced signiﬁcantly (see Table 2), although this
cannot be solely attributed to canagliﬂozin, as the
doses of metformin and gliclazide were also uptitrated.
The patient did not experience any unwanted eﬀects
although the creatinine measurement did increase over
this time. In line with manufacturer recommendations,
the dose was reduced to 100mg in view of the esti-
mated glomerular ﬁltration rate dropping to less
than 60ml/min. Blood pressure recorded in clinic at
the end of July 2015 was 121/68mmHg, which was the
lowest it had ever been since 2007.
At this point the canagliﬂozin was stopped as it
was not felt necessary for his diabetes control and
because of the reduction in estimated glomerular ﬁl-
tration rate. In the next clinic in August 2015, blood
pressure measurement was again high, the lowest
being 151/87mmHg. In view of the apparent remark-
able eﬀect on the patient’s blood pressure, a decision
was made in conjunction with the patient to restart
the canagliﬂozin at a low dose of 100mg daily and
cautiously monitor the kidney function. After re-
starting the canagliﬂozin 100mg in August 2015,
the blood pressure reduced to 138/86mmHg in the
next clinic. The blood pressure remained well con-
trolled at 136/83 at the clinic visit in November 2015.
Discussion
Almost all of the glucose ﬁltered by the glomeruli
is reabsorbed, primarily in the early proximal convoluted
tubule via action of sodium glucose
co-transporter 2, a high-capacity, low-aﬃnity trans-
porter that is selectively expressed in the kidney.1
Sodium glucose co-transporter 2 expression is
increased in humans with diabetes mellitus and
Zucker diabetic fatty rats, correlating with glomerular
hyperﬁltration and increased glucose reabsorption, as
well as increased sodium reabsorption.2 This contrib-
utes to sodium retention and hypertension in diabetic
patients, the two often co-existing. There is also animal
model evidence supporting a role for sodium glucose
co-transporter 2-mediated sodium reabsorption in the
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development of hypertension: in hypertensive rats,
angiotensin II has been shown to regulate the increase
in sodium glucose co-transporter 2 expression via the
angiotensin II AT1 receptor.3
Canagliﬂozin and dapagliﬂozin were two of the
ﬁrst sodium glucose co-transporter 2 inhibitors to
be approved in Europe and the United States for
use in diabetic patients, and others soon followed.
Table 1. Medications the patient was taking prior to the addition of canagliflozin.
Drug Dose Frequency Class
Ramipril 10 mg Once daily Angiotensin-converting enzyme inhibitor
Diltiazem-modified release 200 mg Once daily Calcium channel blocker
Bisoprolol 10 mg Once daily Beta-blocker
Doxazosin-modified release 8 mg Once daily Alpha-adrenoceptor antagonist
Furosemide 40 mg Once daily Loop diuretic
Amiloride 25 mg Once daily Potassium-sparing diuretic
Gliclazide 160 mg Twice daily Sulphonylurea
Isosorbide
mononitrate-modified release
25 mg Once daily Long-acting nitrate
Atorvastatin 80 mg Once daily HMG Co-A reductase inhibitor
Aspirin 75 mg Once daily Antiplatelet
Metformin 1000 mg Twice daily Biguanide
Methotrexate 17.5 mg Once weekly Antifolate disease modifying drug
Folic acid 5 mg Once weekly N/A
Etanercept 10 mg Once weekly TNF inhibitor
Table 2. Timeline of the patient’s blood test results, weight and clinic blood pressure in relation to canagliflozin dose.
Clinic date
26
February
2015
8
June
2015
8
July
2015
20
July
15
6
August
2015
20
August
2015
1
October
2015
12
November
2015
HbA1c, mmol/mol 103 61 40 49
Best clinic BP, mmHg 177/99 137/80 121/68 151/87 138/86 147/85 136/83
Sodium, mmol/L 135 142 142 141 142 141 137
Potassium, mmol/L 4.1 4.3 4.1 4.4 4.1 4.2 4.8
Urea, mmol/L 6.0 6.0 6.5 4.9 6.1 5.7 7.9
Creatinine, mmol/L 97 107 120 105 105 96 114
eGFR, ml/min 67 60 52 61 61 68 56
Weight, kg 119 113.9 113.9 113.1 112.7
Canagliflozin, daily dose 100 mg started
May 2015
Increased
to 300 mg
Reduced
to 100 mg
Stopped Restarted
100 mg
100 mg 100 mg 100 mg
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Our experience with the patient in this case study is
expected to be a class eﬀect, not speciﬁc to canagli-
ﬂozin. Clinical trials with these agents have consist-
ently shown beneﬁcial eﬀects not only on diabetes
control but also on blood pressure and weight.
They have been shown to produce a reduction in
HbA1c of around 0.9%, a mean reduction in weight
of 2.5 kg, a drop in systolic blood pressure of
4mmHg and a drop in diastolic blood pressure of
1.6mmHg.4–6 In the recently published EMPA-
REG study, it has been shown that the sodium glu-
cose co-transporter 2 inhibitor empagliﬂozin reduces
cardiovascular mortality by 38% and all-cause mor-
tality by 32%, in high cardiac risk type 2 diabetes
mellitus patients.5 It has also been shown to reduce
heart failure mortality by 35% and this been attrib-
uted, in part, to eﬀects on blood pressure, amongst
other things.7
Sodium glucose co-transporter 2 inhibitors have
been postulated to reduce blood pressure via their
osmotic diuretic action.1 They work on a diﬀerent
site to loop diuretics and thiazides, which act on the
thick ascending limb of the loop of Henle´ and the
distal convoluted tubule, respectively. Caution is
advised when used in combination with loop diuretics
such as furosemide due to risk of hypovolaemia,
although concomitant use is not contra-indicated.
Typical characteristics of patients with resistant
hypertension include co-morbidities such as obesity
and type 2 diabetes, as well as obstructive sleep
apnoea, older age, target organ damage and athero-
sclerotic vascular disease.8 It could be argued that
sodium glucose co-transporter 2 inhibitors can play
a role in the management of such patients not only
for their diabetes but also for their high blood pres-
sure and obesity. However, such medications should
be used under close supervision in patients with
chronic kidney disease and in those taking a combin-
ation of diuretics.
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